Compare Cassava Sciences Inc (FLNA) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Sony Group Corp — how do they compare? Cassava Sciences Inc trades at $0.94 (market cap $47.75M), while Sony Group Corp trades at $23.51 (market cap $138.43B). The key difference: Sony Group Corp is far larger — about 2899.1× Cassava Sciences Inc's market cap, and Sony Group Corp pays a 0.67% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | SONY | |
|---|---|---|
Market Cap | $47.75M | $138.43B |
Sector | Health | Technology |
52-Week High | $4.64 | $30.26 |
52-Week Low | $0.87 | $19.32 |
Enterprise Value | -$34.93M | $136.35B |
Dividend Yield | — | 0.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.9528, down 4.46% today, with a bearish technical outlook but strong analyst support (66.7% buy ratings). The company continues to post net losses and negative cash flows, though recent EPS beats show some operational improvement. Recent news highlights Q2 2026 results and business updates on Tuberous Sclerosis Complex therapies.
The outlook remains speculative due to persistent unprofitability and cash burn, but analyst optimism and a low P/B ratio of 0.75 may attract value investors. Key risks include execution challenges in drug development and reliance on financing amid negative earnings.
Sony's stock is trading at $23.48, down 1.43% over the past day, with a bullish technical outlook supported by moving averages. The company reported strong cash flow of $1.07 trillion in 2025 and beat EPS estimates in two of the last three quarters, though Q1 2026 was a miss. Recent news highlights success from Spider-Man: Brand New Day and a joint venture with TSMC for image sensors, signaling growth in entertainment and technology segments.
The investment outlook is positive, driven by analyst consensus favoring a buy rating (68.75%) and potential upside from blockbuster films and sensor innovation. Key risks include a projected net loss in 2026, competitive pressures in gaming, and currency volatility. Fundamentals show solid revenue but margin compression, requiring careful monitoring of profit trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
